Abivax (ABVX) Operating Expenses (2022 - 2026)
Abivax (ABVX) posted quarterly Operating Expenses of -$67.4 million for Q1 2026, down 32.96% year-over-year from -$100.5 million in Q1 2025, and down 113.49% on a QoQ basis from $499.6 million in Q4 2025.
Abivax (ABVX) Operating Expenses (2022 - 2026) Analysis & Trends
Abivax (ABVX) has reported Operating Expenses for 5 consecutive years, with -$67.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 32.96% year-over-year to -$67.4 million; the TTM figure through Mar 2026 stood at $281.5 million (up 44.68% YoY), while the FY2025 annual figure was $291.7 million, up 47.23% from the prior year.
- Operating Expenses came in at -$67.4 million for Q1 2026 at Abivax, down from $499.6 million in the prior quarter.
- The five-year high for Operating Expenses was $499.6 million in Q4 2025, with the low at -$96.7 million in Q3 2025.
- Average Operating Expenses over 5 years is $38.8 million, with a median of -$49.8 million recorded in 2024.
- Across the five-year window, Operating Expenses tumbled 137.38% in 2023 and soared 256009642.09% in 2024, its largest moves.
- Year by year, Operating Expenses stood at -$56.93 in 2022, then sank by 137.38% to -$135.14 in 2023, then soared by 256009642.09% to $346.0 million in 2024, then surged by 44.4% to $499.6 million in 2025, then sank by 113.49% to -$67.4 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered -$67.4 million, $499.6 million, and -$96.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | -716.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | 15.76 Mn |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 1.10 Bn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 1.85 Bn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | - |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | -919.00 Mn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 898.54 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | 445.22 Mn |
| 10 | Abivax | - | - | - | -67.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -67.40 Mn |
| Dec 31, 2025 | 499.57 Mn |
| Sep 30, 2025 | -96.75 Mn |
| Jun 30, 2025 | -53.87 Mn |
| Mar 31, 2025 | -50.69 Mn |
| Dec 31, 2024 | 345.97 Mn |
| Sep 30, 2024 | -56.57 Mn |
| Jun 30, 2024 | -44.10 Mn |
| Mar 31, 2024 | -49.82 Mn |
| Dec 31, 2023 | -135.14 |
| Dec 31, 2022 | -56.93 |